title: Down-regulation of CK2 activity results in a decrease in the level of cdc25C phosphatase in different prostate cancer cell lines.
abstract: Protein kinase CK2 is implicated in the regulation of the cell cycle. In addition to a variety of functions, CK2 has anti-apoptotic properties. So far the role of CK2 linking both pathways in the cell is not clear. Some years ago we found that CK2 phosphorylates cdc25C, one member of the cdc25 family of proteins. In this study, we showed that inhibition of CK2 activity by three different inhibitors led to a down-regulation of the level of cdc25C. Inhibition of CK2 activity by transfecting the dominant-negative CK2α subunit also resulted in a down-regulation of the level of cdc25C whereas inhibition of CK2α' had no effect on the cdc25C level. In both cases, we observed apoptosis by PARP cleavage as well as by an increase in γH2AX phosphorylation. These results show that down-regulation of the level of cdc25C is not a prerequisite for the induction of apoptosis.
authors.affiliation: Medizinische Biochemie und Molekularbiologie, Universität des Saarlandes, Gebäude 44, 66421 Homburg, Germany.
authors.forename: Carolin C
authors.initials: CC
authors.lastname: Schneider
authors.forename: Claudia
authors.initials: C
authors.lastname: Götz
authors.forename: Andrea
authors.initials: A
authors.lastname: Hessenauer
authors.forename: Jürgen
authors.initials: J
authors.lastname: Günther
authors.forename: Sabine
authors.initials: S
authors.lastname: Kartarius
authors.forename: Mathias
authors.initials: M
authors.lastname: Montenarh
mesh_terms: D000880:Anthraquinones / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D001562:Benzimidazoles / Q000494:pharmacology; D016203:CDC2 Protein Kinase / Q000378:metabolism; D047390:Casein Kinase II / Q000037:antagonists & inhibitors / Q000378:metabolism*; D045744:Cell Line, Tumor; D015536:Down-Regulation / Q000187:drug effects; D005799:Genes, Dominant / Q000235:genetics; D006801:Humans; D008297:Male; D050505:Mutant Proteins / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D014162:Transfection; D014230:Triazoles / Q000494:pharmacology; D020687:cdc25 Phosphatases / Q000378:metabolism*
chemical_list: C492322:2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole; C405354:4,5,6,7-tetrabromobenzotriazole; D000880:Anthraquinones; D001562:Benzimidazoles; D050505:Mutant Proteins; D047428:Protein Kinase Inhibitors; D014230:Triazoles; C543211:1,2,5,8-tetrahydroxy anthraquinone; D047390:Casein Kinase II; D016203:CDC2 Protein Kinase; D020687:cdc25 Phosphatases